Items where authors include "Buch, M.H."

Export as [feed] Atom [feed] RSS
Number of items: 12.

Article

Sandercock, P., Darbyshire, J., DeMets, D. et al. (2050 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15. 924. ISSN 2041-1723

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology. ISSN 2213-8587

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. ISSN 0140-6736

Dumitru, R.B., Bissell, L., Erhayiem, B. et al. (8 more authors) (2023) Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change. ACR Open Rheumatology, 5 (2). pp. 71-80. ISSN 2578-5745

Lescoat, A., Murphy, S.L., Chen, Y.T. et al. (5 more authors) (2022) Symptom experience of limited cutaneous systemic sclerosis from the Patients’ perspective: A qualitative study. Seminars in Arthritis and Rheumatism, 52. 151926. ISSN 0049-0172

Corinaldesi, C., Ross, R.L., Abignano, G. orcid.org/0000-0002-1479-0133 et al. (8 more authors) (2021) Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. International Journal of Molecular Sciences, 22 (6). 2894. ISSN 1661-6596

Lescoat, A., Roofeh, D., Townsend, W. et al. (6 more authors) (2021) Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. BMJ Open, 11 (3). e044765. ISSN 2044-6055

Lescoat, A., Murphy, S.L., Roofeh, D. et al. (17 more authors) (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 6 (1). 66 -76. ISSN 2397-1983

Peytrignet, S., Denton, C.P., Lunt, M. et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324

Herrick, A.L., Pan, X., Peytrignet, S. et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases. ISSN 0003-4967

Buch, M.H., Conaghan, P., Quinn, M.A. et al. (3 more authors) (2004) True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α? Annals of the Rheumatic Diseases, 63 (10). pp. 1344-1346. ISSN 0003-4967

Proceedings Paper

Cheung, W.C., Shukla, R., Dumitru, R. et al. (8 more authors) (2023) POS0627 Blood-Based Protein Biomarkers Are Associated With Subclinical Cardiovascular Abnormalities As Defined By Cardiovascular Magnetic Resonance Imaging In Systemic Sclerosis (Ssc) Patients. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 587-588.

This list was generated on Sat Apr 13 08:52:54 2024 BST.